In a letter to Missouri's House Committee on Health and Mental Health Policy, the Cystic Fibrosis Foundation expressed its support for HB 1628, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
Site Search
In a letter to Maryland's Senate Finance Committee and House Health and Government Operations Committee, the Cystic Fibrosis Foundation expressed its support for HB 879/SB 595, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements as well as ban alternative funding prog
In a letter to Oregon's Senate Committee on Health Care, and later to the full Senate, the Cystic Fibrosis Foundation expressed its support for HB 4113, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to Connecticut's House Committee on Insurance and Real Estate, the Cystic Fibrosis Foundation provided feedback on HB 5054 which would establish an affordability board with the goal to improve access to and affordability of care for Connecticuters.
In a letter to the Virginia Senate Committee on Commerce and Labor, the Virginia House Committee on Labor and Commerce, and all members of the House of Delegates, the Cystic Fibrosis Foundation provided feedback on SB 274/HB 570 which would establish an affordability board with the goal to improve access to and affordability of care for Virginia
In a letter to Nebraska's Banking, Commerce and Insurance Committee, the Cystic Fibrosis Foundation provided feedback on LB 833 which would establish an affordability board with the goal to improve access to and affordability of care for Nebraskans.
In comments provided to the Florida Health Care Administration, the Cystic Fibrosis Foundation joined a coalition of patient groups to express support for expanding eligibility for the Children’s Health Insurance Program in Florida and urged legislators to remove premium requirements.
In a letter to the House Energy & Commerce Health Subcommittee, the Foundation joins a cohort of patient organizations to stress the importance of addressing antimicrobial resistance and prioritize the passage of the PASTEUR Act.
In a letter to the House Energy & Commerce Committee, the Cystic Fibrosis Foundation states its support for legislation that addresses antimicrobial resistance, orphan drug exclusivity, and access to specialized care across state lines.
In a letter to the Department of Health and Human Services and the Domestic Policy Council, the Cystic Fibrosis Foundation joined the Partnership to Protect Coverage in urging for the prompt finalization of a number of pending rules that will greatly advance affordable, accessible, and adequate healthcare coverage.